CytoMed Therapeutics Limited (GDTC)

NASDAQ · Health care · Pharmaceutical Preparations · Financial statements, TTM figures and earnings dates

In fiscal year 2025 (ended December 31, 2025), CytoMed Therapeutics Limited reported revenue of SGD 324.4K and net income of −SGD 4.0M. Annual financial statements are available for fiscal years 2020 to 2025, taken from the company's filings with the SEC.

Open interactive financials →

Key financials

SGD	FY2025 2025-12-31	FY2024 2024-12-31	FY2023 2023-12-31	FY2022 2022-12-31	FY2021 2021-12-31
Income statement
Revenue	SGD 324.4K	SGD 69.5K	–	–	–
Net income	−SGD 4.0M	−SGD 2.5M	−SGD 4.1M	−SGD 3.1M	−SGD 2.1M
Diluted EPS	−SGD 0.34	−SGD 0.22	−SGD 0.39	−SGD 0.40	−SGD 0.30
Cash flow
Operating cash flow	−SGD 3.7M	−SGD 2.7M	−SGD 3.5M	−SGD 1.4M	−SGD 1.7M
Capital expenditure	SGD 637.9K	SGD 1.4M	SGD 58.3K	SGD 473.8K	SGD 582.4K
Free cash flow	−SGD 4.3M	−SGD 4.1M	−SGD 3.6M	−SGD 1.9M	−SGD 2.3M
Balance sheet
Cash and equivalents	SGD 2.1M	SGD 4.7M	SGD 6.2M	SGD 1.6M	SGD 2.5M
Total assets	SGD 8.0M	SGD 10.1M	SGD 12.4M	SGD 5.2M	SGD 6.1M
Total liabilities	SGD 1.1M	SGD 1.0M	SGD 1.1M	SGD 4.6M	SGD 3.5M
Total debt	SGD 409.5K	SGD 432.0K	SGD 441.7K	SGD 803.6K	SGD 924.8K
Shareholders' equity	SGD 6.5M	SGD 9.0M	SGD 11.2M	SGD 587.0K	SGD 2.6M

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SGD as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full GDTC page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open GDTC financials →